Compass Therapeutics

Compass Therapeutics(CMPX)

BOSTON, MA
Biotechnology1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Antibody Therapies

Compass Therapeutics is a life sciences company focused on Antibody Therapies.

OncologyNeurology
Funding Stage
PUBLIC
Open Jobs
2

Pipeline & Clinical Trials

Freedom SCS System
Back Pain
N/A
N/A
Clinical Trials (1)
NCT04203992Videogame for the Prevention of Doping and Supplement Abuse in Teenage Athletes
N/A
Enhanced DBT-A
Suicidality
N/A
Clinical Trials (1)
NCT07256496Enhanced Dialectical Behavior Therapy for Adolescents
N/A
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
Treatment Resistant Depression
N/A
Clinical Trials (1)
NCT04519957Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
N/A
Phase 1
Phase 1
Clinical Trials (1)
NCT06150664A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT07419841A Phase 1 Study of the Safety and Tolerability of CTX-10726
Phase 1
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT06548412CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Phase 1/2
Phase 2
Clinical Trials (1)
NCT05513742A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT05481736Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
Phase 2
Phase 2
Clinical Trials (1)
NCT04433858An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Phase 2
Phase 2
Clinical Trials (1)
NCT04433845The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Phase 2
Phase 2
Clinical Trials (1)
NCT04739865The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
Phase 2
Phase 2
Clinical Trials (1)
NCT05220410The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Phase 2
Phase 2
Clinical Trials (1)
NCT03775200The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Phase 2
Phase 2
Clinical Trials (1)
NCT05381974The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
Phase 2
Phase 2
Clinical Trials (1)
NCT05733546A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Phase 2
Phase 2
Clinical Trials (1)
NCT05312151The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Phase 2
Phase 2
Clinical Trials (1)
NCT04661514Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
Phase 2
Phase 2
Clinical Trials (1)
NCT04656301Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
Phase 2
Phase 2/3
Clinical Trials (1)
NCT05506943A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Phase 2/3
Phase 3
Clinical Trials (1)
NCT05711940Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Phase 3
Phase 3
Clinical Trials (1)
NCT06247839The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Phase 3
Phase 3
Clinical Trials (1)
NCT05624268Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
Phase 3

Open Jobs (2)

Principal Analytical Scientist, CMC

Boston, MA
Manufacturing
1w ago
From $140K/yr

Executive Assistant

Boston, MA
Executive/C-Suite
1mo ago
From $82K/yr
Interview Prep Quick Facts
Portfolio: 22 clinical trials
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 2 active jobs

Financials (FY2025)

Revenue
$850K
R&D Spend
$42M(4981%)11%
Net Income
-$49M
Cash
$43M
Source: SEC 10-K Filing

Hiring Trend

Stable
2
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub